{
  "trial_id": "NCT02110810",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "randomly assigned to receive a 100 mg suppository of indomethacin or 2.4 g of glycerin suppository immediately afterwards while still under sedation",
      "label": "met"
    },
    {
      "criterion": "all patients are observed to prevent spontaneous expulsion of the suppository until they became completely awake",
      "label": "met"
    },
    {
      "criterion": "all patients, staff endoscopists, residents, and researchers are blinded to the treatment assigned to each of them",
      "label": "met"
    },
    {
      "criterion": "a clinical history, particularly patient-related risk factors for post-ERCP pancreatitis; blood test results for the determination of basal amylase, liver enzymes, and bilirubin levels; as well as results of ultrasonography of the liver and biliary tract",
      "label": "met"
    },
    {
      "criterion": "all data generated during the ERCP is being recorded, particularly those related to procedure-related risk factors for developing acute pancreatitis",
      "label": "met"
    },
    {
      "criterion": "any adverse events related to the rectally applied indomethacin or glycerin suppositories are being recorded as expulsion, irritation, or bleeding",
      "label": "met"
    },
    {
      "criterion": "post-ERCP pancreatitis is considered the main outcome variable and is defined as the development of new or increased abdominal pain consistent with pancreatitis, and elevated blood amylase or lipase >3 times the upper limit of normal until 24 h after the procedure",
      "label": "met"
    },
    {
      "criterion": "the severity is determined according to consensus guidelines, with mild post-ERCP pancreatitis resulting in hospitalization of less than 3 days, and moderate post-ERCP pancreatitis resulting in hospitalization of 4-10 days",
      "label": "met"
    },
    {
      "criterion": "severe post-ERCP pancreatitis is qualified as resulting in a hospitalization of >10 days, or leading to the development of pancreatic necrosis or pseudocysts, or requiring percutaneous or surgical intervention",
      "label": "met"
    },
    {
      "criterion": "patients with acute pancreatitis are being followed up for 30 days after hospital discharge",
      "label": "met"
    },
    {
      "criterion": "asymptomatic hyperamylasemia is defined as any amylase level at least three times above the normal serum level in the absence of abdominal pain",
      "label": "met"
    },
    {
      "criterion": "follow up The patients are kept under surveillance in the endoscopy recovery area for 3 h after ERCP. Measurement of serum amylase is determined at 2 h post-ERCP in all included patients",
      "label": "met"
    }
  ],
  "exclusion": [
    {
      "criterion": "unwillingness or inability to consent for the study",
      "label": "unknown"
    },
    {
      "criterion": "pregnancy",
      "label": "not_met"
    },
    {
      "criterion": "breast feeding",
      "label": "not_met"
    }
  ],
  "notes": "The patient is a 41-year-old obese woman coming to the emergency room with abdominal pain and vomiting. She drinks alcohol frequently and does not smoke.",
  "_meta": {
    "topic_id": "57",
    "trial_id": "NCT02110810",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}